Related Experiment Video

Updated: May 31, 2026

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
12:17

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions

Published on: May 8, 2017

Azithromycin, Ureaplasma and chronic lung disease of prematurity: a case study for neonatal drug development

Mark A Turner1, Evelyne Jacqz-Aigrain, Sailesh Kotecha

  • 1Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

Archives of Disease in Childhood
|June 24, 2011
PubMed

Insights

Chronic lung disease (CLD) in preterm infants may be linked to Ureaplasma. Azithromycin, an antibiotic, is explored for its potential to reduce CLD by targeting inflammation and infection.

Area of Science:

  • Neonatal Medicine
  • Pulmonology
  • Infectious Diseases

Background:

  • Chronic lung disease (CLD) is a significant cause of illness and death in premature infants.
  • Ureaplasma has been investigated as a potential factor in CLD development.
  • Pulmonary inflammation is recognized as a contributor to CLD.

Purpose of the Study:

  • To review the evidence linking Ureaplasma to CLD in preterm infants.
  • To examine the anti-inflammatory and anti-infective properties of azithromycin.
  • To discuss challenges in drug development for preventing CLD.

Main Methods:

  • Literature review of studies on Ureaplasma and CLD.
  • Analysis of azithromycin's dual action (anti-inflammatory and anti-infective).
  • Examination of the drug development pipeline for CLD interventions.

Main Results:

  • Evidence suggests a potential role for Ureaplasma in CLD pathogenesis.
  • Azithromycin's properties make it a candidate for CLD prevention.
  • Drug development faces significant hurdles before clinical application.

Conclusions:

  • Further research is needed to confirm Ureaplasma's role in CLD.
  • Azithromycin warrants investigation as a therapeutic agent for CLD prevention.
  • Addressing drug development obstacles is crucial for clinical translation.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...